Clinical study patient id: (b)(6).It was reported that on (b)(6) 2017, a 25mm trifecta gt valve was successfully implanted.On (b)(6) 2022, echocardiogram showed a deterioration in the function of the aortic valve.Transesophageal echocardiogram (tee) was planned for further diagnostics on (b)(6) 2022.The patient was reported to be in stable condition.
|
An event of regurgitation and valve deterioration was reported.A more comprehensive assessment, including a histopathological examination of the valve tissue, could not be performed as the device remains implanted and was not returned for analysis.However, based on the information received, the reported valve degeneration is consistent with structural valve deterioration (svd), which is a well-known complication of tissue heart valve replacement surgery.A variety of factors may contribute to svd, including patient, biological, and implant-related factors: no implant related factors could be confirmed from the information received from the field as information related to implant procedure was not provided.Biological factors which can result in tissue degeneration, such as calcification (from patient conditions predisposing to elevated calcium like renal disease etc.) or thinning of the prosthetic leaflet tissue (predisposing to leaflet tears) also could not be confirmed as the valve was not returned for histopathological examination.The device history record was also reviewed to ensure that each manufacturing and inspection operation was performed and that the product met all specifications.Based on the available information, the root cause of the reported event of regurgitation and valve deterioration could not be conclusively determined.H6: clinical code 4582 was removed.
|